Evaluation of an internal cyclotron target for the production of 211At via the 209Bi (α,2n)211At reaction

[1]  I. Vergote,et al.  Alpha-particle radiotherapy with 211At-labeled monodisperse polymer particles, 211At-labeled IgG proteins, and free 211At in a murine intraperitoneal tumor model. , 1995, Gynecologic Oncology.

[2]  M. Zalutsky,et al.  Cytotoxicity of α-particle-emitting m-[211At]astatobenzylguanidine on human neuroblastoma cells , 1994 .

[3]  R. McLendon,et al.  Radioimmunotherapy of Neoplastic Meningitis in Rats Using an α-Particle-emitting Immunoconjugate , 1994 .

[4]  Ø. Bruland,et al.  Preparation and quality control of 211At‐labelled and 125I‐labelled monoclonal antibodies. Biodistribution in mice carrying human osteosarcoma xenografts , 1994 .

[5]  E. Rofstad,et al.  Inactivation of human osteosarcoma cells in vitro by 211At-TP-3 monoclonal antibody: comparison with astatine-211-labeled bovine serum albumin, free astatine-211 and external-beam X rays. , 1994, Radiation research.

[6]  E. Rofstad,et al.  Analysis of the therapeutic gain in the treatment of human osteosarcoma microcolonies in vitro with 211At-labelled monoclonal antibody. , 1994, British Journal of Cancer.

[7]  J. S. Mitchell,et al.  The development of a [211At]-astatinated endoradiotherapeutic drug: Part II. Therapeutic results for transplanted adenocarcinoma of the rectum in mice and associated studies. , 1994, International journal of radiation oncology, biology, physics.

[8]  R. Vessella,et al.  Preparation and evaluation of para-[211At]astatobenzoyl labeled anti-renal cell carcinoma antibody A6H F(ab')2. In vivo distribution comparison with para-[125I]iodobenzoyl labeled A6H F(ab')2. , 1993, Nuclear medicine and biology.

[9]  I. Vergote,et al.  211At-labelling of polymer particles for radiotherapy : synthesis, purification and stability , 1993 .

[10]  J. Roeske,et al.  Dosimetry of intraperitoneally administered radiolabeled antibodies. , 1993, Medical physics.

[11]  E. M. Link,et al.  211At-methylene blue for targeted radiotherapy of human melanoma xenografts: treatment of cutaneous tumors and lymph node metastases. , 1992, Cancer research.

[12]  C. Pelizzari,et al.  Modeling of dose to tumor and normal tissue from intraperitoneal radioimmunotherapy with alpha and beta emitters. , 1990, International journal of radiation oncology, biology, physics.

[13]  D. Bigner,et al.  Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[14]  M. Zalutsky,et al.  Astatination of proteins using an N-succinimidyl tri-n-butylstannyl benzoate intermediate. , 1988, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.

[15]  J. Humm.  A microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy. , 1987, International journal of radiation oncology, biology, physics.

[16]  A. Harrison,et al.  Efficacy of astatine-211-labeled monoclonal antibody in treatment of murine T-cell lymphoma. , 1987, NCI monographs : a publication of the National Cancer Institute.

[17]  S. Mirzadeh,et al.  Cyclotron isotopes and radiopharmaceuticals—XXXV astatine-211☆ , 1985 .

[18]  A. M. Friedman,et al.  Preparation of a biologically stable and immunogenically competent astatinated protein. , 1977, International journal of nuclear medicine and biology.

[19]  J. Huizenga,et al.  EXCITATION FUNCTIONS OF BISMUTH AND LEAD , 1959 .

[20]  D. R. Corson,et al.  Artificially Radioactive Element 85 , 1940 .